Skip to main content

Advertisement

Table 3 CEC, V-CEC, and CEP levels among different clinical conditions

From: Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy

  CEC V-CEC CEP
Variable Coef* (cells/μL) p value Coef (cells/μL) p value Coef (cells/μL) p value
Tumor bearing −0.57 0.74 −1.08 0.46 0.10 0.44
Chemotherapy regimen*
CEF 0.04 0.99 0.65 0.82 0.12 0.64
Liposomal doxorubicin −3.00 0.58 −0.43 0.92 −0.03 0.93
N-HDFL 1.79 0.70 3.22 0.40 0.20 0.55
TCH −1.42 0.63 −0.55 0.82 0.01 0.98
TEC 1.08 0.79 2.50 0.45 0.27 0.32
TH (Ref)   (Ref)   (Ref)  
G-CSF use 0.03 0.85 −0.02 0.86 −0.004 0.78
  1. *Coef = adjusted regression coefficient.
  2. *CEF: cyclophosphamide, epirubicin, fluorouracil.
  3. N-HDFL: vinorelbine, continuous infusion fluorouracil and leucovorin.
  4. TCH: docetaxel, carboplatin, herceptin.
  5. TEC: docetaxel, epirubicin, cyclophosphamide.
  6. TH: docetaxel, herceptin.